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https://doi.org/10.1016/j.molcel.2020.12.006SUMMARYChromatin is a barrier to efficient DNA repair, as it hinders access and processing of certain DNA lesions.
ALC1/CHD1L is a nucleosome-remodeling enzyme that responds to DNA damage, but its precise function
in DNA repair remains unknown. Here we report that loss of ALC1 confers sensitivity to PARP inhibitors,
methyl-methanesulfonate, and uracil misincorporation, which reflects the need to remodel nucleosomes
following base excision by DNA glycosylases but prior to handover to APEX1. Using CRISPR screens, we
establish that ALC1 loss is synthetic lethal with homologous recombination deficiency (HRD), which we attri-
bute to chromosome instability caused by unrepaired DNA gaps at replication forks. In the absence of ALC1
or APEX1, incomplete processing of BER intermediates results in post-replicative DNA gaps and a critical
dependence on HR for repair. Hence, targeting ALC1 alone or as a PARP inhibitor sensitizer could be em-
ployed to augment existing therapeutic strategies for HRD cancers.INTRODUCTION
Repair of DNA double-strand breaks (DSBs) and protection of
damaged replication forks is essential for normal cell growth,
presents a barrier to cancer development, and shapes the
cellular response to radio- and chemotherapies (Chapman
et al., 2012). Cancer cells often exhibit altered DNA repair net-
works, which confer a selective growth advantage to the tumor
by potentiatingmutator phenotypes and thus driving cancer evo-
lution. Homologous recombination (HR), an essential mecha-
nism of DSB repair and fork protection, is one such DNA repair
pathway that is frequently attenuated in cancer. Importantly, de-
ficiencies in the HR pathway create a vulnerability that can be ex-
ploited to selectively kill cancer cells by means of synthetic
lethality (O’Neil et al., 2017). The paradigm for this approach is
the use of poly(ADP)-ribose polymerase inhibitors (PARPi) for
the treatment of homologous recombination-deficient (HRD)Molecular Cell 81, 767–783, Febr
This is an open access article undcancers, which includes breast and ovarian tumors that are
mutated in the HR genes BRCA1 and BRCA2 (Bryant et al.,
2005; Farmer et al., 2005). Despite the notable success of PARPi
in the clinic, approximately half of HRD cancers fail to respond to
treatment due to innate PARPi resistance, and of those that do
respond, >90% ultimately develop acquired PARPi resistance
(Noordermeer and van Attikum, 2019). As such, there is an ur-
gent clinical need to identify new therapeutic strategies to
improve existing treatments to target HRD and exploit other
DNA repair vulnerabilities that exist in cancer, including defi-
ciencies in non-homologous end joining, mismatch repair,
base excision repair (BER), and ATM signaling (Gourley
et al., 2019).
DNA of eukaryotic cells is compacted into chromatin, and this
higher-order complex structure ensures the maintenance of
cellular identity. As nucleosomes are perceived as barriers for
DNA-related processes, they must first be disassembled or re-uary 18, 2021 ª 2020 The Author(s). Published by Elsevier Inc. 767
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
(legend on next page)
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substrate. While most bulk chromatin packaging occurs during
DNA replication, where histones are evicted ahead of the fork
and, together with newly synthesized histones, are re-assem-
bled behind the fork (Hammond et al., 2017), chromatin re-orga-
nization outside of S phase impacts on fundamental processes
such as transcription and DNA repair. In particular, dynamic
changes in chromatin organization occur on damaged chromatin
to facilitate timely access of DNA repair enzymes (Price and
D’Andrea, 2013). Nucleosome eviction and/or sliding are neces-
sary for chromatin relaxation, as well as prompt nucleosome
deposition after removal of the DNA lesion (Ransom et al.,
2010). Diverse types of chromatin-remodeling complexes cata-
lyze such chromatin transactions with related ATPase motor
translocase domains. Specialized chromatin remodelers involve
four subfamilies: imitation switch (ISWI), chromodomain helicase
DNA-binding (CHD), switch/sucrose non-fermentable (SWI/
SNF), and INO80 (Clapier et al., 2017; Stadler and Richly,
2017). Different subfamilies preferentially achieve particular out-
comes, such as facilitating chromatin access for DNA repair
transactions, and are targeted to specific chromatin domains
via regulatory cues.
ALC1 (amplified in liver cancer 1), also known as CHD1L (chro-
modomain-helicase-DNA-binding protein 1-like), is an ISWI-
related chromatin remodeler encoded by a gene on chromo-
some 1q21, a region commonly amplified inmany cancers (Flaus
et al., 2006). ALC1 is differentiated from other members of the
ISWI-related remodelers by virtue of a C-terminal macro domain,
which possesses high intrinsic affinity for poly(ADP)-ribose (PAR)
chains (Ahel et al., 2009). Through its macro domain, ALC1 is
rapidly recruited to sites of DNA damage by PAR chains synthe-
sized by PARP1/2 (Ahel et al., 2009; Satoh and Lindahl, 1992).
Macro domain binding to PAR chains also relieves an autoinhibi-
tory interaction between the macro and ATPase domains of
ALC1, which activates ATP hydrolysis and nucleosome sliding
(Lehmann et al., 2017; Singh et al., 2017). ALC1-dependent chro-Figure 1. Loss of Alc1 does not affect lifespan and reduces DEN-induc
(A) Top: Schematic representation of mouse Alc1 genomic locus. The gene-tra
genomic locus is 49.461 kb, and introns (lines) and exons (bars) are approximately
organization. Alc1 mutant protein is truncated at the 45th amino acid and fused t
(B) Weight analysis of Alc1+/+ and Alc1/ mice. Error bars are not shown to rend
measured at each time point.
(C) Tumor-free survival of Alc1mice. Significance: Mantel-Cox test, p = 0.4. n = 3
dermatitis, overgrown teeth, and fits) were excluded from this study. Right: Freque
both groups.
(D–F) Alc1/ mice show reduction in both spontaneous epithelial and mesenchy
free survival of Alc1mice. Significance: Mantel-Cox test, p = 0.1. n = 30 Alc1+/+ a
overgrown teeth, and fits) were excluded from this study. Right: Frequency of A
tendency for Alc1/ mice to develop less epithelial and mesenchymal tumors.
epithelial tumors. Note the presence a stomach adenoma with peculiar hyaline
sentative images ofmesenchymal tumors. Note the presence an hemangiosarcom
of liver from 36-week-old Alc1+/+ and Alc1/ male mice intraperitoneally injected
Right: Tumor size measurement in mm. Each tumor has been measured with a c
p < 0.0001.
(G and H) Alc1/ MEFs are sensitive to PARPi. (G) Reduced survival of Alc1/
treated cells (n = 3 biologically independent experiments). (H) Growth curves in
doses. Data are mean ± SEM (n = 3 biologically independent experiments).
(I) Reduced survival of Alc1/ MEFs after treatment with MMS. Data are me
periments).ns, p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.matin remodeling has been proposed to facilitate DNA repair, but
evidence in support of this role is currently lacking (Tsuda et al.,
2017). Moreover, the precise DNA repair and organismal func-
tions of ALC1 remain unknown.
Herewe show that nucleosome remodeling byALC1 is required
downstream of base excision by DNA glycosylases but upstream
of APEX1. Loss of ALC1 leads to toxic BER intermediates that
result in single-strand gap formation and replication fork collapse.
Since blocking this process in cells confers PARPi sensitization
and a critical dependence on HR, our study establishes ALC1
as a potential therapeutic target for treating HRD cancers.
RESULTS
To investigate the role of ALC1 in vivo, we derived an Alc1
knockout mouse model from a gene trap embryonic stem cell
line (E305F08) available from the German Gene Trap consortium
(GGTC). Mapping by splinkerette PCR located the insertion site
within the first intron at position 4827, which is predicted to
disrupt the ALC1 protein before the helicase ATP binding
domain, leading to a chimeric gene containing part of Alc1
exon1 fused to b-galactosidase (Figure 1A). This was confirmed
by genotyping of wild-type (WT), heterozygous, andmutant mice
and the corresponding mouse embryonic fibroblasts (MEFs)
(Figures S1A and S1B), and western blotting confirmed loss of
ALC1 protein expression (Figure S1C). Although Alc1/ mice
are viable, they were born at slightly reduced sub-Mendelian ra-
tios (14% versus 25%; Figure S1D) and are of smaller size than
their WT littermates throughout adulthood, independent of
gender (Figure 1B; Figure S1E). Despite their reduced size, adult
Alc1/ mice do not present with increased DNA damage in
different tissues (Figure S1F) and do not develop any other
phenotypic abnormalities that would impact on their total life-
span. Indeed, Alc1+/+ and Alc1/ mice have a similar overall
survival time (around 600 days; Figure S1G). Hence, loss of
ALC1 alone has no effect on lifespan.ed tumor occurrence
p vector rsFROSAbgeo0s is inserted at position 4827 in intron 1. The whole
to scale. Gray lines represent primers used for genotype. Bottom: ALC1 protein
o the b-Geo cassette of the gene-trap vector.
er the graph readable; data are from males and females with at least five mice
0 Alc1+/+ and n = 30 Alc1/. Mice culled due to nonspecific phenotypes (e.g.,
ncy of Alc1mice that develop tumors. Note that there is no difference between
mal and DEN-induced tumor formation. (D) Epithelial and mesenchymal tumor-
nd n = 30 Alc1/. Mice culled due to nonspecific phenotypes (e.g., dermatitis,
lc1 mice that develop epithelial or mesenchymal tumors. Note that there is a
Significance: Fisher’s exact test, p = 0.2. (E) Left: Representative images of
pink cells in the Alc1+/+ mouse. Scale bars represent 100 mm. Right: Repre-
a in the spleen ofAlc1+/+mouse. Scale bars represent 100 mm. (F) Left: Pictures
with DEN (25 mg/kg body) at 2 weeks of age and fed with high-fat diet. n = 6.
aliper. Note the smaller-sized tumors in the Alc1/ group. Significance: t test,
MEFs after treatment with Olaparib. Data are mean ± SEM normalized to un-
Alc1+/+ and Alc1/ MEFs in non-treated controls and with indicated Olaparib
an ± SEM normalized to untreated cells (n = 3 biologically independent ex-







Figure 2. Defective PAR-binding and nucleosome remodeling confers PARPi and MMS sensitivity
(A–D) ALC1/ cells are sensitive to PARPi and MMS. (A) CRISPR-mediated inactivation of ALC1 in eHAP. Immunoblot of WCEs in ALC1+/+ and ALC1/ cells,
probed for ALC1. hnRNPA1 was used as a loading control. (B) Schematic representation of survival assays using CellTiter-Glo. (C and D) Reduced survival of
eHAP ALC1/ cells after treatment with indicated genotoxin. Data are mean ± SEM normalized to untreated cells (n = 3 biologically independent experiments).
Solid lines show a nonlinear least-squares fit to a four-parameter dose-response model.
(E and F) PARP trapping contributes to Olaparib sensitivity in ALC+/+ and ALC1/ cells. (E) Immunoblot of WCEs versus chromatin in ALC1+/+ and ALC1/ cells
following indicated treatments, probed for ALC1, PARP1, and PARP2. a-tubulin was used as a loading control for cytoplasmic fraction. Histone H3 was used as a
loading control for chromatin fraction (data are representative of n = 3 biologically independent experiments). (F) Rescue of Olaparib sensitivity in inducible CAS9
(iCAS9) ALC1+/+ and ALC1/ eHAP-expressing PARP1 sgRNA following 72 h Dox induction. Data are mean ± SEM normalized to untreated cells (n = 3 bio-
logically independent experiments). Solid lines show a nonlinear least-squares fit to a four-parameter dose-response model.
(G) Rescue of Olaparib sensitivity in iCAS9ALC1/ eHAP-expressing PARP2 sgRNA following 72 hDox induction. Data aremean ± SEMnormalized to untreated
cells (n = 3 biologically independent experiments). Solid lines show a nonlinear least-squares fit to a four-parameter dose-response model.
(H) Rescue of Olaparib sensitivity in iCAS9 ALC1+/+ and ALC1/ eHAP-expressing PARG sgRNA following 72 h Dox induction. Data are mean ± SEM normalized
to untreated cells (n = 3 biologically independent experiments). Solid lines show a nonlinear least-squares fit to a four-parameter dose-response model.
(legend continued on next page)
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and tumorigenesis in mice, we established a tumor watch cohort
of 30 Alc1+/+ and 30 Alc1/ mice for approximately 22 months.
We observed that tumor latency is similar in both groups
(673 days for Alc1+/+ versus 658 days for Alc1/; Figure 1C).
General tumor incidence was also unaffected by loss of ALC1,
as 67%ofAlc1/mice (20/30) presentedwith at least one tumor
compared to 73% for theirWT littermates (22/30). 53%ofAlc1+/+
(16/30) versus 43% of Alc1/ (13/30) presented with more than
one tumor (Figure 1C; Figure S1H). Sub-dividing tumors into
three different categories (lymphomas, epithelial, or mesen-
chymal; Table 1) revealed that although lymphoma-free survival
(median survival time: 734 days for Alc1/ versus 755 days for
Alc1+/+; Figure S1I, left panel) and incidence of lymphomas (Fig-
ure S1I, right panel) are similar in Alc1+/+ and Alc1/ mice,
epithelial or mesenchymal tumor-free survival tended to be
increased in Alc1/ mice (734 days for mice lacking ALC1
versus 671 days for their WT littermates; Figure 1D, left panel;
Figure S1J). Moreover, Alc1/ mice exhibited a tendency to
develop fewer epithelial or mesenchymal tumors compared to
their WT littermates (Figure 1D, right panel). Indeed, 57% of
Alc1+/+ mice developed epithelial-mesenchymal tumors
whereas only 37% of Alc1/ mice were affected. Moreover,
epithelial tumor-free survival tended to be slightly increased for
mice lacking ALC1, with a median survival of 741 days for
Alc1/ compared to 695 days for Alc1+/+ (Figure S1J, left panel)
accompanied by a mild decrease in the number of Alc1/ mice
developing one or more than one tumor (Figure S1J, middle and
right panel). Interestingly, Alc1/mice do not appear to develop
mesenchymal tumors (Figure S1K). These data suggest that lack
of ALC1 may protect against development of epithelial and
mesenchymal tumors.
To further test this hypothesis, we induced the formation of
epithelial tumors in livers of both Alc1+/+ and Alc1/ mice via
a single intraperitoneal administration of the carcinogen diethyl-
nitrosamine (DEN; 25 mg/kg body weight) into 2-week-old mice
followed by feeding with a high-fat diet until the mice reached
36 weeks of age. This study revealed that Alc1/ mice devel-
oped significantly smaller liver tumors than Alc1+/+ mice (Fig-
ure 1F) following DEN injection. Furthermore, histology analysis
showed that all tumors are hepatocellular adenomas (Fig-
ure S1L), with a moderate decrease in number in Alc1-deficient
mice suggesting that Alc1/ mice are less susceptible to devel-
opment of epithelial liver tumors than WT animals. Hence, ALC1
loss in mice confers a tendency toward reduced tumor burden.
To determine if and how DNA repair processes are altered in
the absence of ALC1, we exposed Alc1/ MEFs to genotoxins.
While we observed no differences in proliferative capacity be-(I) Rescue of Olaparib sensitivity in iCAS9 ALC1+/+ and ALC1/ eHAP-express
untreated cells (n = 3 biologically independent experiments). Solid lines show a n
(J) Representative images (n = 3 biologically independent experiments) of clonog
sgRNA following 72 h Dox ± 250 nM Olaparib.
(K) Quantification of clonogenic survival assays in ALC1+/+ and ALC1/ iCAS9 cel
mean ± SEM normalized to non-treated ALC1+/+ NT sgRNA (n = 3 biologically in
(L) Olaparib sensitivity is associated with defective nucleosome remodeling. ALC1
SEM normalized to untreated cells (n = 3 biologically independent experiment
response model.tween Alc1+/+ and Alc1/ MEFs under normal growth condi-
tions, Alc1/ MEFs exhibited sensitivity to the alkylating agent
methyl-methanesulfonate (MMS) (Figure 1H). Unexpectedly,
given that ALC1 is recruited to sites of DNA damage in a PAR-
dependent manner, Alc1/ MEFs also showed exquisite PARPi
sensitivity as measured by cell survival or proliferative capacity
(Figures 1I and 1J). Depletion of ALC1 has also scored as sensi-
tizing human cells to PARPi in unbiased CRISPR screens, but the
basis of this was unclear (Liu et al., 2020; Zimmermann
et al., 2018).
To confirm these findings in human cells, we examined the
response of diploid ALC1+/+ and ALC1/ eHAP cells to a range
of DNA-damaging agents (Figures 2A–2D; Figures S2A–S2G).
Similar to what we observed in MEFs (Figures 1H–1J), loss of
ALC1 conferred exquisite sensitivity to the PARPi Olaparib (Fig-
ures 2A–2C), Veliparib, and Talazoparib (Figures S2A and S2B).
Further screening of genotoxic compounds confirmed sensitivity
to MMS (Figure 2D) and revealed mild sensitivity to hydroxyurea
(HU; Figure S2C). However, ALC1/ eHAP cells were not sensi-
tive to camptothecin (CPT), aphidicolin, etoposide, or cisplatin
(Figures S2D–S2G), indicating that ALC1 is dispensable for the
repair of the DNA lesions induced by these genotoxins. Impor-
tantly, sensitivity to Olaparib and MMS was also observed in
ALC1/ U2OS cells (Figures S2H–S2J) and Alc1/ MEFs (Fig-
ures 1H–1J), indicating that the selective genotoxin sensitivity is
not cell-type or species specific.Loss of ALC1 confers enhanced PARP trapping on
chromatin
PARPi toxicity has been ascribed to both the catalytic inhibition
of PARP1 and the trapping of PARPs on chromatin (Bryant et al.,
2005; Farmer et al., 2005; Lord and Ashworth, 2017; Murai et al.,
2012). To determine how PARP trapping contributes to PARPi
toxicity inALC1/ cells, we conducted stringent chromatin frac-
tionations to assess the levels of PARP1 and PARP2 on chro-
matin. These experiments revealed increased PARP1 and
PARP2 trapping in ALC1/ cells relative to WT controls (Fig-
ure 2E), which was further increased upon treatment with Ola-
parib, MMS, or a combination (Figure 2E). Furthermore, deletion
of PARP1 conferred PARPi resistance in both ALC1+/+ and
ALC1/ cells (Figure 2F; Figures S2K–S2M), which confirmed
that PARP trapping contributes to but is not solely responsible
for the ALC1 loss/PARPi synthetic phenotype. Notably, PARP1
depletion increased sensitivity to MMS in both ALC1+/+ and
ALC1/ cells (Figure S2N), indicating that increased PARP1
trapping (Figure 2E) is a consequence but not the cause of
MMS toxicity in these cells. These data suggest that PARP1ing 53BP1 sgRNA following 72 h Dox. Data are mean ± SEM normalized to
onlinear least-squares fit to a four-parameter dose-response model.
enic survival assays in ALC1+/+ and ALC1/ iCAS9 cells expressing indicated
ls expressing indicated sgRNAs following 72 hDox ± 250 nMOlaparib. Data are
dependent experiments).
+/+ and ALC1/ eHAP transduced with indicated constructs. Data are mean ±
s). Solid lines show a nonlinear least-squares fit to a four-parameter dose-
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pendent of ALC1 status.
To investigate the contribution of PARP2 trapping described in
Figure 2E to PARPi toxicity, we measured PARPi sensitivity in
both ALC1+/+ and ALC1/ cells following knockout of PARP2.
Loss of PARP2 alone had no effect on the viability of ALC1+/+
and ALC1/ cells (Figures S2O and S2P). Interestingly,
knockout of PARP2 led to increased PARPi sensitivity in
ALC1+/+ cells but conversely suppressed PARPi sensitivity in
ALC1/ cells (Figure 2G). Loss of PARP2 had little effect on
MMS sensitivity in ALC1+/+ and ALC1/ cells (Figure S2Q).
These data indicate that increased PARP2 trapping contributes
to the increased PARPi sensitivity observed in ALC1/ cells.
ALC1 protects PAR chains from degradation by PARG
A previous study observed that overexpression of ALC1 or the
ALC1 macro domain alone (Ahel et al., 2009) results in
increased levels of PAR chains in cells, which are normally
degraded by the PAR-glycosylase, PARG (Lin et al., 1997;
Slade et al., 2011). We therefore considered the possibility
that the ALC1 macro domain might bind and protect PAR
chains from PARG degradation. Indeed, purified ALC1 macro
domain, when incubated with ADP-ribosylated PARP1 or
PARylated nucleosomes, protected PAR chains from degrada-
tion by human PARG (Figures S2T and S2U). In contrast, PAR
protection was attenuated with the PAR-binding mutant ALC1-
macro D723A (Figure S2T). Hence, binding by the macro
domain of ALC1 protects PAR chains from degradation by
PARG in vitro. Interestingly, depletion of PARG partially
rescued sensitivity to Olaparib in both ALC1+/+ and ALC1/
cells (Figure S2R; Figure 2H), suggesting that loss of PARG
does not require ALC1 to confer PARPi resistance. Notably,
PARG depletion showed a much more pronounced rescue of
MMS sensitivity in ALC1/ cells when compared to ALC1+/+
(Figure S2S), suggesting that loss of PAR protection by ALC1
may contribute to MMS sensitivity in ALC1/ cells.
Since loss of 53BP1 has been shown to permit DSB resection
and restore HR in BRCA1-deficient tumors, which is one source
of PARPi resistance (Bunting et al., 2010), we investigated if al-
terations in 53BP1 impact the PARPi sensitivity of ALC1/ cells.
Notably, deletion of 53BP1 (Figure S2V) conferred PARPi resis-
tance in both ALC1+/+ and ALC1/ cells but did not affect
MMS sensitivity (Figure 2I; Figure S2W). Colony-forming assays
(CFAs) confirmed suppression of Olaparib sensitivity following
loss of PARP1, PARG, and 53BP1 (Figures 2J and 2K). Further-
more, loss of PARP1 did not confer synthetic lethality with ALC1
deficiency (Figures 2J and 2K).
Finally, complementation of ALC1/ cells with WT, but not a
PAR-binding mutant ALC1-G750E (Singh et al., 2017) nor a
nucleosome-remodeling-deficient ATPase-dead ALC1-K77R
mutant (Ahel et al., 2009), was able to rescue sensitivities to
both PARPi and MMS (Figure 2L; Figures S2X–S2AB). These
data establish that PARPi sensitivity in ALC1/ cells reflects a
requirement for both PAR binding and nucleosome remodeling
and is caused by increased PARP trapping but not loss of
PARP enzymatic activity.
Our data indicate that PARPi toxicity is mediated by PARP1
trapping in both ALC1+/+ andALC1/ cells. Similarly, increasing772 Molecular Cell 81, 767–783, February 18, 2021basal levels of PARylation through knockout of PARG or shifting
the balance in favor of resection by depletion of 53BP1 rescues
PARPi sensitivity independently of ALC1 status. Interestingly,
knockout of PARP2 partially rescues PARPi sensitivity specif-
ically in ALC1/ but not in ALC1+/+ cells. While these data sug-
gest a role of ALC1 in PARP2 turnover on chromatin, the rescue
was incomplete, indicating there are likely additional factors that
are responsible for PARPi sensitivity in ALC1/ cells. We
observe elevated levels of chromatin-bound PARP1 and
PARP2 in ALC1/ cells even in untreated conditions.We reason
that trapping of this increased chromatin-bound population of
PARP molecules upon PARPi treatment is responsible for the
increased PARPi sensitivity observed in ALC1/ cells. Howev-
er, the mechanism driving the increase in PARP1 and PARP2
on chromatin in ALC1/ cells remains unclear.
Whole-genome CRISPR screens identify ALC1-specific
vulnerabilities
ALC1 has previously been suggested to act in the BER pathway,
based on epistasis with PARP1 loss and delayed kinetics of sin-
gle-strand break repair (Tsuda et al., 2017). To test if PARPi
sensitivity observed in ALC1/ cells could be explained by a
loss of BER activity, we generated inducible knockouts of BER
genes in ALC1+/+ and ALC1/ cell lines (Figure S3A). Analysis
of single and double knockout cell lines did not show evidence
of growth impairment or synthetic lethality between ALC1 and
any of the BER gene knockouts tested (Figures S3B and S3C).
Moreover, PolB-, EXO1-, and LIG3-depleted cells showed mod-
erate PARPi sensitivity in CFAs (Figures S3B and S3C), and their
loss had an additive effect when depleted in ALC1/ cells. In
contrast, FEN1 depletion had little effect on PARPi sensitivity in
either ALC1+/+ or ALC1/ cells (Figures S3D–S3H). The lack
of epistasis between ALC1 loss and depletion of these BER
genes suggests that the sensitivity to PARPi observed in the
absence of ALC1 cannot simply be explained by a general loss
of BER activity and that the relation between BER and ALC1 is
more complex than previously assumed.
To investigate the mechanisms of PARPi sensitization and to
identify genetic vulnerabilities in ALC1/ cells, we performed
whole-genome CRISPR screens using inducible Cas9 (iCas9)
diploid eHAP cells containing Lenti-gRNA against ALC1 or
non-targeting (NT) control, without or treated with 250 nM Ola-
parib (Figure 3A). Comparison of NT gRNA non-treated versus
Olaparib confirmed that ALC1 gRNA sensitizes cells to low-
dose Olaparib, while gRNAs targeting PARP1 or PARG
conferred PARPi resistance, as documented above (Figure 3B).
From the genome-wide screen, histone PARylation factor 1
(HPF1) scored as the top hit when comparing NT gRNA + Ola-
parib versus NT gRNA + untreated. Loss of HPF1 is known to
confer PARPi sensitivity (Gibbs-Seymour et al., 2016) and was
recently shown to modulate the catalytic activity of PARP1 (Bilo-
kapic et al., 2020; Suskiewicz et al., 2020). Comparison of NT
gRNA + Olaparib versus ALC1 gRNA + Olaparib also
revealed that the viability of ALC1/ cells is significantly
impaired by depletion of DUT, HR factors (BRCA2, RAD51,
RAD51C, CHD4), factors that promote DSB resection (RAD50,
UBE2N/UBC13, and DNA2), or the DSB-sensing kinase ATM
(Figures 3C and 3D).
A B
C D
Figure 3. CRISPR screens identify novel
synthetic lethalities with ALC1 deficiency
(A) Schematic of screening pipeline.
(B) Volcano plot of p value versus log-fold change
(LFC), iCAS9 eHAP NT gRNA non-treated versus
NT gRNA + 250 nM Olaparib.
(C) Immunoblot of WCEs in eHAP iCAS9 NT gRNA
and ALC1 gRNA from 3 independent biological
replicates following 144 h Dox, probed for ALC1;
a-tubulin was used as a loading control.
(D) Volcano plot of p value versus LFC, iCAS9
eHAP NT gRNA + 250nM Olaparib versus ALC1
gRNA + 250 nM Olaparib.
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To validate the hits from the CRISPR screens, we first depleted
HPF1 in ALC1+/+ and ALC1/ cells to determine if PARPi sensi-
tivity in ALC1/ cells is epistatic with HPF1 (Figure S4A). HPF1
loss conferred enhanced sensitivity to PARPi in both ALC1+/+
and ALC1/ cells (Figures S4B–S4D) but had little effect on
MMS sensitivity (Figure S4E). This suggests that PARPi and
MMS sensitivity in ALC1/ cells is not mediated by HPF1.
Next, we sought to confirm the loss of viability observed with
combined depletion of ALC1 and HR factors. To this end, we
successfully generated DLD-1 BRCA2+/+ ALC1/ cells, but
failed to recover any DLD-1BRCA2/ALC1/ clones, reinforc-
ing the notion that ALC1 loss is synthetic lethal with HRD. In
further support of this possibility, DLD BRCA2/ clones with
reduced ALC1 expression (Figure 4A) exhibited severely
impaired proliferative capacity and hyper-sensitivity to Olaparib
(Figure 4B; Figure S4F). Synthetic lethality between ALC1 and
HRD was further suggested in ALC1/ cells subject to siRNAMoleculaagainst either BRCA1 or BRCA2 (Figures
4C and 4D; Figure S4G). BRCA2
silencing in ALC1/ cells also conferred
exquisite PARP inhibitor andMMS sensi-
tivity (Figure 4E; Figures S4H–S4J).
To examine if deleting 53BP1 could
restore viability in ALC1/ BRCA1/
BARD1-depleted cells, we generated
ALC1 knockouts in WT and 53BP1-
deleted clones of BARD1AID/AID HCT-
116 cells (Figure S4K), a cell line engi-
neered to encode biallelic auxin-depen-
dent degron tags at the BARD1 C termi-
nus (Nakamura et al., 2019). Treatment
of cells with inodole-3-acetic acid (IAA)
led to rapid and stable BARD1 degrada-
tion (Nakamura et al., 2019) (Figure S4G),
which resulted in synthetic lethality in
ALC1/ cells but not in the WT controls
(Figure 4F). Notably, knockout of 53BP1
rescued synthetic lethality in ALC1/
BARD1-depleted cells (Figure 4G), indi-
cating that restoration of HR is sufficient
to rescue synthetic lethality between
ALC1 and BRCA1/BARD1 deficiencies.
Furthermore, synthetic lethality betweenALC1 loss and HRD could be rescued by complementation
with WT ALC1, but not by ALC1-G750E or ALC1-K77R mutants
(Figure 4H), indicating that both PARbinding and nucleosome-re-
modeling activities of ALC1 are important in this context.
Our CRISPR dropout screen also identified UBC13 as sensi-
tizing ALC1-deficient cells to PARPi (Figure 3D). Similar to loss
of BRCA1, BARD1, or BRCA2, depletion of UBC13, which com-
promises DSB resection and template switching, reduced the
viability of ALC1/ cells and conferred hyper-sensitivity to
PARPi and MMS (Figures S4M–S4Q). In addition, the DSB acti-
vated checkpoint kinase ATM also scored as a hit for sensitizing
ALC1-depleted cells to PARPi (Figure 3D). Depletion of ATM
conferred sensitivity to PARPi in ALC1+/+cells, with ALC1/
cells showing hyper-sensitivity (Figures 4I–4L) and similar sensi-
tivity in response to MMS (Figures S4R). Collectively, these data
show that deficiencies in HR, DSB processing, or the DSB-
sensing kinase ATM confer synthetic growth defects and PARPi
hyper-sensitization when combined with loss of ALC1.r Cell 81, 767–783, February 18, 2021 773
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of HRD cancers, we next examined if expression levels of ALC1,
BRCA1/2, or ATM influence breast cancer survival in human pa-
tients. We observed no relationship between ALC1 expression
and BRCA1 or ATM in this analysis. Interestingly, we observed
a significantly increased hazard ratio in patients with tumors ex-
pressing low levels of BRCA2 and high levels of ALC1 (Fig-
ure 4M). Moreover, Kaplan-Meier survival analysis revealed
poor survival in this cohort (Figure 4N). These data suggest
that high levels of ALC1 in BRCA2low tumors results in a more
aggressive disease with poorer prognosis. This raises the possi-
bility that targeting ALC1 could improve the survival outcome in
patients with HRD cancers.
Mechanism of ALC1/HRD synthetic lethality
To further explore the basis of synthetic lethality between ALC1
loss and HRD, we first examined metaphase spreads for
changes in chromosome integrity. Depletion of BRCA1 or
BRCA2 alone conferred the expected increase in chromosome
abnormalities on metaphase spreads, consistent with loss of
HR. Strikingly, knockdown of BRCA1 or BRCA2 in ALC1/ cells
resulted in a significant increase in chromosomal abnormalities
at metaphase and increased micronuclei when compared to
ALC1+/+ cells depleted for HR (Figures 5A–5C; Figure S5A). Cells
lacking both ALC1 and HR also presented with a lower percent-
age of cells in S phase and an increase in the sub-G1 population
(Figures S5B and S5C).
Since HR plays a critical role in the protection of damaged
replication forks (Ray Chaudhuri et al., 2016; Schlacher et al.,
2011), we analyzed replication dynamics in ALC1+/+ and
ALC1/ cells ± HRD by DNA fiber assay. When compared toFigure 4. Defective ALC1-mediated nucleosome remodeling confers s
(A–E) Loss of ALC1 is synthetic lethal with HRD and leads to PARPi hypersensit
transduction with LentiCRISPR NT sgRNA and ALC1 sgRNA and clonal selection
ALC1. a-tubulin was used as a loading control. (B) Olaparib colony survival in DLD-
ALC1Low expression. Data aremean ± SEM normalized to untreated cells (n = 3 indep
a four-parameter dose-response model. (C) Survival in ALC1+/+ and ALC1/ eHA
survival was measured using CellTiter-Glo. Data are mean ± SEM normalized to A
and ALC1/ eHAP cells transfected with BRCA2-targeting siRNAs. Cell survival w
cells (n = 3 independent biological experiments). (E) Olaparib survival in ALC1+/+ a
Data are mean ± SEM normalized to untreated cells (n = 3 independent biological
dose-response model.
(F) Quantification of a crystal violet proliferation assay in parental and ALC1-delet
experiments).
(G) Quantification of a crystal violet proliferation assay in parental and ALC1-delet
biological experiments).
(H) ALC1+/+ and ALC1/ eHAP cells transduced with indicated ALC1 construct
siRNAs. Cell survival was measured using CellTiter-Glo. Data are mean ± SEM
periments).
(I) Immunoblot of WCEs in ALC1+/+ and ALC1/ iCAS9 eHAP cells transduced w
ATM. a-tubulin is used as a loading control.
(J) Representative images (n = 3 biologically independent experiments) of clono
ATM sgRNA following 72 h Dox ± 250 nM Olaparib.
(K) Quantification of clonogenic survival assays in ALC1+/+ and ALC1/ iCAS9
Olaparib. Data are mean ± SEM normalized to non-treated ALC1+/+ NT sgRNA (
(L) Olaparib survival of ALC1+/+ and ALC1/ iCAS9 cells transduced with NT sgR
untreated cells (n = 3 independent biological experiments). Solid lines show a no
(M) Hazard ratio analysis of breast cancer patients from TGCA according to ALC
(N) KM survival analysis of BRCA2low breast cancer patients from TGCA ac
0.001; ****p < 0.0001.control cells, we detected a modest but significant increase in
fork speed in ALC1/ cells, which has also been reported
upon silencing of PARP1 (Maya-Mendoza et al., 2018). Knock-
down of BRCA1 or BRCA2 further increased fork speeds in
ALC1/ cells, suggestive of unrestrained fork progression (Fig-
ures S5D andS5E).ALC1/ cells depleted for BRCA1 or BRCA2
also presented with a significant increase in replication fork
asymmetry relative to controls, which is indicative of increased
replication fork stalling and/or collapse (Figures S5E and S5F).
We next considered the possibility that loss of ALC1 might
lead to the accumulation of ssDNA gaps during DNA replication,
whichwould place a critical dependence onHR andBRCA1/2 for
fork stabilization and repair. To test this hypothesis, we tested for
the presence of ssDNA gaps at replication forks using amodified
DNA fiber assay, which includes S1 nuclease degradation of sin-
gle-stranded DNA (ssDNA) (Quinet et al., 2017). Neither ALC1/
nor HR-deficient cells exhibited a detectable reduction in the
IdU/CldU ratio upon S1 nuclease treatment (Figures 5D and
5E), indicating that ssDNA gaps are not detectable in these con-
texts. However, since HR is proficient in ALC1/ cells, ssDNA
gaps could be missed due to repair by HR in this context.
Consistent with this possibility, ALC1/ cells subjected to
siRNA depletion of BRCA1 or BRCA2 exhibited a significant
reduction in the IdU/CldU ratio (Figures 5D and 5E), which sug-
gests that ALC1 loss leads to ssDNA gaps that accumulate
when HR repair is compromised. In agreement with this conclu-
sion, EdU-positive ALC1/ cells showed elevated levels of
RAD51 foci, consistent with replication-associated activation
of HR (Figures 5F and 5G). Furthermore, knockdown of BRCA1
or BRCA2, which abolish RAD51 focus formation, conferred sig-
nificant elevation in the number of ssDNA binding protein RPAynthetic lethality with HRD
ivity. (A) Immunoblot of WCEs from DLD-1 WT and BRCA2/ cells following
(no BRCA2/ALC1 double knockouts were recovered), probed with BRCA2 and
1BRCA2+/+ ALC1+/+,BRCA2/ALC1/,BRCA2/ALC1+/+, andBRCA2/
endent biological experiments). Solid lines show a nonlinear least-squares fit to
P cells transfected with BRCA1-targeting short interfering RNAs (siRNAs). Cell
LC1+/+ cells (n = 3 independent biological experiments). (D) Survival in ALC1+/+
asmeasured using CellTiter-Glo. Data are mean ± SEM normalized to ALC1+/+
nd ALC1/ eHAP transfected with non-targeting or BRCA2-targeting siRNAs.
experiments). Solid lines show a nonlinear least-squares fit to a four-parameter
ed BARD1AID/AID cells ± IAA. Data are mean ± SD (n = 3 independent biological
ed 53BP1/BARD1AID/AID cells ± IAA. Data are mean ± SD (n = 3 independent
s were transfected with non-targeting, BRCA1-targeting, or BRCA2-targeting
normalized to ALC1+/+ cells for each siRNA (n = 3 independent biological ex-
ith ATM sgRNA following 72 h Dox, probed with antibodies against ALC1 and
genic survival assays in ALC1+/+ and ALC1/ iCAS9 cells expressing NT and
cells expressing NT sgRNA and ATM sgRNA following 72 h Dox ± 250 nM
n = 3 biologically independent experiments).
NA and ATM sgRNA following 72 h Dox. Data are mean ± SEM normalized to
nlinear least-squares fit to a four-parameter dose-response model.
1 and BRCA2 expression.
cording to ALC1 expression. ns, p > 0.05; *p < 0.05; **p < 0.01; ***p <
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Figure 5. Loss of HR leads to single-stranded gaps at replication forks and gross genomic instability in ALC1–/– cells
(A–D) Knockdown of BRCA1/2 in ALC1/ cells results in genome instability. (A) Representative micrographs of metaphase spreads in ALC1+/+ and ALC1/
eHAP transfected with the indicated siRNA. (B) Quantification of the number of aberrant chromatids per metaphase in ALC1+/+ and ALC1/ eHAP transfected
with indicated siRNA. Data are mean ± SEM (n = 3 independent biological experiments). (C) Quantification of number of micronuclei per primary nucleus from
ALC1+/+ and ALC1/ eHAP cells transfected with non-targeting, BRCA1-targeting, and BRCA2-targeting siRNAs. Data are means from individual experiments;
bar represents median (n = 3 independent biological experiments). (D) Lower: scheme of the nucleotide labeling and S1 nuclease treatment strategy used for gap
detection at the replication fork. Upper: Representative DNA fiber immunofluorescence images from ALC1/ eHAP cells transfected with the indicated siRNAs
and treated or not with S1 nuclease.Scale bars represent 100 mm.
(legend continued on next page)
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OPEN ACCESSArticlefoci (Figures S5G and S5H), which likely correspond to sites of
ssDNA gaps. Accumulation of ssDNA gaps also resulted in acti-
vation of a robust DDR, including increased pS1981 ATM,
gH2AX and 53BP1 foci, and activation of apoptosis as evident
from cleaved caspase-3 and PARP1 cleavage (Figure 5H; Fig-
ures S5I–S5N).ALC1 is required for the removal of dUTP
misincorporation in DNA
Prompted by the results of our CRISPR screen, we next exam-
ined the genetic interaction between ALC1 andDUT, an essential
enzyme that dephosphorylates dUTP to dUMP and hence pro-
vides dUMP as a precursor for thymidine synthesis as well as
limiting the intracellular pool of dUTP (Hirmondo et al., 2017).
CFAs established that deletion of DUT is lethal in both ALC1+/+
and ALC1/ cells (Figures S6A and S6B). Our results from the
CRISPR screen showed that, despite being essential, DUT drops
out of the ALC1 sgRNA arm faster than in non-targeting sgRNA,
suggestive of a negative effect of DUT depletion in ALC1/ cells
(Figure 3D). Since elevated levels of dUTP lead to increased ura-
cil misincorporation into DNA (Vértessy and Toth, 2009), we
considered the possibility that the impact on viability of ALC1/
cells following depletion of DUT may reflect a defect in dealing
with misincorporated uracil in DNA. To test this possibility,
ALC1+/+ and ALC1/ cells were exposed to the uracil analogs
dU, formyl-dU, or FU (Figures 6A and 6B; Figure S6C). This
experiment revealed sensitivity of ALC1/ cells specifically to
formyl-dU (Figure 6B), which results in a misincorporated lesion
that is normal excised from DNA by the uracil DNA glycosylase
SMUG1 (Masaoka et al., 2003). Re-introduction of WT ALC1 in
ALC1/ cells restored formyl-dU sensitivity to the same levels
as in ALC1+/+ cells, confirming that sensitivity is due to loss of
ALC1 (Figures 6B and 6C).
To further investigate a role for ALC1 in uracil removal from
DNA in vivo, we generated ALC1+/+ and ALC1/ cells with
inducible knockouts for the uracil glycosylases UNG, MBD4,
and SMUG1 (Hashimoto et al., 2012; Haushalter et al., 1999;
Krokan et al., 2001) (Figure 6D; Figures S6D and S6E). Surpris-
ingly, depletion of SMUG1 in ALC1/ cells rescued formyl-dU
sensitivity (Figure 6E), but not sensitivity to MMS or PARPi (Fig-
ures S6F and S6G). In contrast, knockout of UNG or MBD4 had
no effect on sensitivity to Olaparib, MMS, or formyl-dU (Figures
S6H–S6M). UNG knockout did, however, reduce the fitness of
ALC1/ cells (Figures S6N and S6O). Since SMUG1 can
compensate for uracil incision by UNG (Kavli et al., 2002; Nilsen
et al., 2001), this toxicity could be driven by increased SMUG1
activity. This suggests that SMUG1 itself creates toxic lesions
in the absence of ALC1, at least with respect to formyl-dU. These(E) Boxplot showing mean IdU/CldU ratio in ALC1+/+ and ALC1/ eHAP transfec
500–600 fibers/condition are represented as mean ± SD (2 technical replicates f
(F) Representativemicrographs of ALC1+/+ andALC1/ eHAP cells transfected w
Scale bar, 10 mm.
(G) Quantification of nuclear RAD51 foci in CSK pre-extracted EdU+ and EdUAL
knockdown. Data are means from individual experiments; bar represents media
(H) Immunoblot of WCEs in ALC1+/+ and ALC1/ cells transfected with non-
pSer1981, ATM, CHK2, CHK1-pSer345, total CHK1, RPA-pSer33, total-RPA, gH
used as a loading control. ns, p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001; ****p <results also exclude endogenous uracil misincorporation as the
source of MMS or PARPi sensitivity in ALC1/ cells.
Similar to that observedwithMMS (Figure S2N), loss of PARP1
further sensitized both ALC1+/+ and ALC1/ cells to formyl-dU
(Figure S6P). Knockout of both PARG and 53BP1 partially
rescued formyl-dU sensitivity in ALC1/ cells only (Figures
S6Q and S6R). Interestingly, knockout of PARP2 led to increased
formyl-dU sensitivity in ALC1+/+ cells while conferring moderate
resistance in ALC1/ cells (Figure S6S), similar to that observed
with PARPi (Figure 2G). Having observed that sensitivity to
PARPi and MMS in ALC1-deficient cells is greatly exacerbated
by loss of BRCA1/2, UBC13, or ATM, we also examined if the
same is true for sensitivity to formyl-dU. Indeed, loss of
BRCA2, UBC13, or ATM led to formyl-dU hypersensitivity in
ALC1-deficient cells, which provides further evidence that HR
is required as a backup repair pathway in ALC1/ cells in
response to a range of genotoxin lesions (Figures 6F–6H).Loss of ALC1 is epistatic with APEX1
Wenext sought to understand at which point in the BER pathway
ALC1 acts using formyl-dU as a source of DNA lesions. Removal
of formyl-dU is catalyzed by SMUG1, creating an abasic (AP)
site. Once the AP site is formed, the endonuclease APEX1 cata-
lyzes the incision of the DNA backbone, leaving a 50-deoxyribose
phosphate (Figure 6K).
Since recruitment of ALC1 to damage sites requires PARP-
mediated PARylation, we asked whether PARylation occurs as
a direct result of formyl-dU misincorporation or is induced
following base excision by SMUG1. To this end, we generated
SMUG1 knockouts in ALC1+/+ and ALC1/ cells and assayed
PARylation following treatment with formyl-dU. We also sub-
jected cells to PARGi treatment to block the degradation of
any resulting PARylation signal (Figures 6I and 6J). This experi-
ment revealed that PARylation induced in response to formyl-
dU requires SMUG1.
To examine the relationship between APEX1 and ALC1, we
generated APEX1 knockouts in ALC1+/+ and ALC1/ cells.
Intriguingly, loss of both ALC1 and APEX1 did not lead to
increased sensitivity to formyl-dU, MMS, and PARPi (Figures
6M–6O), indicating epistasis between ALC1 and APEX1. To
determine if ALC1 acts upstream or downstream of APEX1, we
examined ALC1 recruitment to chromatin following formyl-dU
treatment in APEX+/+ and APEX/ cells. Treatment of cells
with formyl-dU resulted in robust ALC1 recruitment in both
APEX+/+ and APEX/ cells, indicating that ALC1 acts upstream
of or in parallel to APEX1. In contrast, knockout of SMUG1 pre-
vented ALC1 recruitment to chromatin in response to formyl-dU
(Figures 6P and 6Q).ted with the indicated siRNAs and treated or not with S1 nuclease. Data from
rom 2 independent biological experiments).
ith non-targeting siRNAs stained with RAD51 antibody, EdU click-iT, and DAPI.
C1+/+ andALC1/ eHAP cells transfectedwith indicated siRNAs 72 h following
n (n = 3 biologically independent experiments).
targeting, BRCA1-targeting, or BRCA2-targeting siRNAs, probed with ATM
2AX, PARP1, cleaved caspase-3, BRCA2, BRCA1, and ALC1. a-tubulin was
0.0001.
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OPEN ACCESSArticleFinally, APEX1/ and ALC1/ cells both showed synthetic
lethality with loss of BRCA1/2, with a very modest additive effect
in APEX1/ ALC1/ double knockouts (Figures 6R and 6S).
These data suggest that AP site generation by SMUG1 triggers
PARylation and ALC1 recruitment, with APEX1 acting in parallel
or downstream. Interestingly, a previous report has shown that
APEX1 activity is inhibited in the context of the nucleosome
in vitro (Eccles et al., 2015; Hinz, 2014; Hinz et al., 2015). Our
data raise the possibility that nucleosome remodeling by ALC1
may facilitate efficient APEX1 activity in vivo.
MPG causes MMS, PARPi sensitivity, and synthetic
lethality with HRD in ALC1–/– cells
We next tested if SMUG1 processing of endogenous lesions un-
derpins the synthetic lethality of cells deficient for both ALC1 and
BRCA1/2. Notably, SMUG1 knockout did not significantly
rescue synthetic lethality in ALC1/ cells subject to depletion
of BRCA1/2 (Figures 7A and 7B). These data exclude uracil
misincorporation as the predominant endogenous lesion
responsible for synthetic lethality observed in ALC1- and HR-
deficient cells.
Prompted by these findings, we asked if MPG, a monofunc-
tional glycosylase responsible for the excision of alkylated
base damage (Figure 7C), is responsible for MMS sensitivity in
ALC1/ cells. Strikingly, depletion ofMPG resulted in significant
suppression of MMS sensitivity in ALC1/ cells (Figures 7D andFigure 6. The monofunctional uracil glycosylase SMUG1 and APEX1 m
(A) ALC1+/+ and ALC1/ eHAP are not sensitive to dU. Data are mean ± SEM n
(B) ALC1/ cells are sensitive to formyl-dU. ALC1+/+ and ALC1/ eHAP transdu
cells (n = 3 biologically independent experiments).
(C) Immunoblot of WCEs in ALC1+/+ and ALC1/ cells transduced with indicate
(D and E) SMUG1 knockout rescues ALC1-dependent formyl-dU sensitivity. (D) I
sgRNA and SMUG1 sgRNA following 72 h Dox, probed with ALC1 and SMUG1.
ALC1/ iCAS9 cells transduced with NT sgRNA and SMUG1 sgRNA following 72
biological experiments).
(F) Formyl-dU survival of ALC1+/+ and ALC1/ eHAP cells transfected with non
untreated cells (n = 3 biologically independent experiments).
(G) Formyl-dU survival of ALC1+/+ and ALC1/ eHAP cells expressing NT or UBC
cells (n = 3 biologically independent experiments).
(H) Formyl-dU survival of ALC1+/+ and ALC1/ eHAP cells expressing NT or ATM
(n = 3 biologically independent experiments).
(I) Is PARylation upstream of formyl-dU (red star) removal by SMUG1?
(J) PARylation by PARPs occurs downstream of SMUG1. Immunoblot of WCEs i
SMUG1/ cells with indicated treatments, probed for ALC1, SMUG1, and anti-
(K) Schematic illustrating (BER) repair of formyl-dU (red star). The monofunctiona
(AP) site. The endonuclease APEX1 catalyzes the incision of the DNA backbone,
(L) Immunoblot of WCEs in cells with indicated genotypes probed for ALC1 and
(M) Formyl-dU survival of ALC1+/+ APEX1+/+,ALC1+/+ APEX1/,ALC1/APEX1
cells (n = 3 independent biological experiments).
(N)MMS survival ofALC1+/+ APEX1+/+,ALC1+/+ APEX1/,ALC1/APEX1+/+, an
(n = 3 independent biological experiments).
(O) Olaparib survival of ALC1+/+ APEX1+/+, ALC1+/+ APEX1/, ALC1/ APEX1+/
cells (n = 3 independent biological experiments). Solid lines show a nonlinear lea
(P) Is incision by APEX1 required for ALC1 recruitment?
(Q) ALC1 recruitment is upstream of incision by APEX1. Immunoblot of CSK ch
probed for ALC1, PARP1, SMUG1, and APEX1. a-tubulin and histone H3 were u
(R) Representative images (n = 3 biologically independent experiments) of clo
APEX1+/+, and ALC1/ APEX1/ eHAP cells transfected with non-targeting or
(S) Quantification of clonogenic survival assays in ALC1+/+ APEX1+/+, ALC1+/+ A
with non-targeting or BRCA2-targeting siRNAs ± 50 nM Olaparib. Data are mea
dependent experiments).7E) and conferred moderate rescue of formyl-dU and Olaparib
sensitivity (Figures S7A and S7B). Knockdown of MPG also re-
sulted in a significant rescue of synthetic lethality in ALC1- and
BRCA1/2-deficient cells (Figures 7F–7H) and suppressed Ola-
parib sensitivity in BRCA1/2-depleted cells (Figures S7C–S7H).
These data reveal that processing of endogenous alkylated
base damage by the glycosylase MPG creates a toxic lesion
that contributes to both synthetic lethality with ALC1 deficiency
and PARPi sensitivity in HR-deficient cells.
DISCUSSION
Alternative therapeutic strategies are needed to exploit DNA
repair vulnerabilities in cancers and to mitigate innate and ac-
quired resistance to existing treatments (Noordermeer and van
Attikum, 2019). This study defines ALC1 as a compelling thera-
peutic target, as its loss confers PARPi sensitization, synthetic
lethality with HRD, and a synergistic interaction with ATM defi-
ciency while being largely dispensable for organismal viability.
Our findings that knockout of PARP1 and PARP2 rescued
PARPi sensitivity and did not confer synthetic lethality in
ALC1/ cells (Figures 2E–2K) show that PARPi sensitivity in
ALC1-deficient cells is caused by increased PARP trapping,
but not loss of PARP enzymatic activity per se. We also attribute
PARPi sensitization to loss of nucleosome sliding activity of
ALC1 (Figure 2L) but exclude that this is due to a loss of BERediate formyl-dU sensitivity in ALC1-deficient cells
ormalized to untreated cells (n = 3 independent biological experiments).
ced with indicated constructs. Data are mean ± SEM normalized to untreated
d constructs, probed for ALC1. a-tubulin was used as a loading control.
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Ponceau was used as a loading control. (E) Formyl-dU survival of ALC1+/+ and
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Figure 7. The monofunctional glycosylase MPG drives MMS sensitivity and contributes to synthetic lethality with BRCA1/2 in ALC1-defi-
cient cells
(A and B) Processing of endogenous lesions by SMUG1 does not drive synthetic lethality with BRCA1/2 in ALC1-deficient cells. (A) Immunoblot of WCEs in
ALC1+/+ and ALC1/ iCAS9 cells transduced with NT sgRNA or SMUG1 sgRNA following 72 h Dox and transfected with non-targeting or BRCA1/2-targeting
siRNAs, probed with ALC1, BRCA1, BRCA2, and SMUG1. Ponceau was used as a loading control. (B) Survival in ALC1+/+ and ALC1/ iCAS9 cells transduced
with NT sgRNA or SMUG1 sgRNA following 72 h Dox and transfected with non-targeting or BRCA1/2-targeting siRNAs. Cell survival was measured using
CellTiter-Glo. Data are mean ± SEM normalized to ALC1+/+ cells (n = 3 independent biological experiments).
(C–E) The monofunctional glycosylase MPG drives MMS sensitivity in ALC1-deficient cells. (C) The monofunctional glycosylase MPG catalyzes the removal of
alkylated bases, creating an abasic (AP) site. (D) Immunoblot of WCEs in ALC1+/+ and ALC1/ eHAP transfected with non-targeting or MPG-targeting siRNAs,
probed for ALC1 and MPG. a-tubulin was used as a loading control. (E) MMS survival of ALC1+/+ ALC1/ eHAP cells transfected with non-targeting or MPG-
targeting siRNAs. Data are mean ± SEM normalized to untreated cells (n = 3 independent biological experiments).
(F–H) Processing of endogenous lesions by MPG contributes to synthetic lethality with BRCA1/2 in ALC1-deficient cells. (F) Immunoblot of WCEs in ALC1+/+ and
ALC1/ eHAP transfected with non-targeting, MPG, BRCA1/2-targeting siRNAs, probed with ALC1, BRCA1, BRCA2, andMPG. a-tubulin was used as a loading
control. (G) Representative images (n = 3 biologically independent experiments) of clonogenic survival assays in ALC1+/+ and ALC1/ eHAP cells transfected
with non-targeting, MPG, and BRCA1/2-targeting siRNAs. (H) Quantification of clonogenic survival assays in ALC1+/+and ALC1/ eHAP cells transfected with
non-targeting, MPG, and BRCA1/2-targeting siRNAs. Data are mean ± SEM normalized to non-treated ALC1+/+ (n = 3 biologically independent experiments).
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OPEN ACCESSArticleactivity, as loss of BER is additive with ALC1 deficiency (Figures
S3A–S3G). ALC1/ cells are also synthetic lethal with HRD (Fig-
ures 4C, 4D, and 4F; Figure S4O), which is associated with
elevated levels of genome instability and the accumulation of
ssDNA gaps at replication forks (Figures 5A–5E). Promoting or
restoring HR through the removal of 53BP1 or PARG is sufficient
to rescue PARPi sensitization of ALC1/ cells and synthetic
lethality with BRCA1 (Figures 2I and 4G). Notably, loss of ATM,
which is a frequent event in cancers (Choi et al., 2016), confers
synthetic growth defects and PARPi sensitization in the absence
of ALC1 (Figures 4I–4L). Our survival analysis in breast cancer
patients suggests that tumors with high ALC1 expression com-
bined with low levels of BRCA2 have a poor prognosis (Figures
4Mand 4N). Together, our data suggest that removal or inhibition
of ALC1 could be exploited in HRD- and/or ATM-deficient can-
cers, either alone or in combination with PARPi.
Loss of ALC1 also confers sensitivity to formyl-dU and syn-
thetic growth defects with loss of DUT (Figures 3D and 6B), the
enzyme that limits the intracellular pools of dUTP and thereby
minimizes uracil misincorporation during DNA replication. Con-
trary to our expectation, sensitivity to formyl-dU but not to PARPi
or MMS in ALC1/ cells can be rescued by removing SMUG1
(Figure 6E; Figures S6F and S6G). This implies that SMUG1 is
responsible for creating toxic lesions in response to formyl-dU
specifically in ALC1/ cells. Loss of HR proteins BRCA2,
UBC13, or ATM further sensitizeALC1/ cells to formyl-dU (Fig-
ures 6F–6H), indicating that—similar to MMS—these lesions
place a critical dependence on HR in the absence of ALC1.
Since ALC1 recruitment occurs downstream of SMUG1 but
upstream of APEX1 in response to formyl-dU, our data suggest
that PARP1/2 and ALC1 recognize the AP site created by
SMUG1. Rather than remodeling the nucleosome to allow
SMUG1 access to the lesion, our data suggest that nucleosome
remodeling by ALC1 is required for the effective handover from
SMUG1 to APEX1. Disruption of this process through loss of
either ALC1 or APEX1 leads to the accumulation of toxic lesions.
While the exact nature of these lesions remains unclear, our data
suggest that toxicity does not arise simply from the generation of
AP sites alone, as excision of dU by UNG did not result in toxicity
in either ALC1+/+ or ALC1/ cells (Figures 6A). Interestingly,
SMUG1 has been proposed to catalyze base incision, resulting
in a 30-a,b unsaturated aldehyde and a 50 phosphate (Alexeeva
et al., 2019). This incision intermediate is subsequently removed
from the 30 end by APEX1. It is therefore possible that the accu-
mulation of this SMUG1-dependent incision intermediate drives
formyl-dU toxicity in both ALC1- and APEX1-deficient cells.
Alternatively, remodeling by ALC1 could be required for the effi-
cient release of SMUG1 from chromatin. Indeed, SMUG1 has
been shown to bindwith high affinity to the AP site following exci-
sion of uracil, which has been proposed to inhibit APEX1 activity
(Pettersen et al., 2007).
While the action of SMUG1 underpins the formyl-dU sensitivity
of ALC1/cells, removal of endogenous uracil lesions by
SMUG1 does not explain the synthetic lethality we observed be-
tween ALC1 and HR. This suggests that a relatively low number
of endogenous uracil lesions are processed by SMUG1 and im-
plicates an alternative lesion as the source of synthetic lethality
with HR. By analogy, we reasoned that sensitivity to MMS couldbe driven via a similar mechanism through the action of the gly-
cosylase MPG, which excises alkylation damage. Indeed,
knockdown of MPG was sufficient to rescue MMS sensitivity in
ALC1/ cells (Figures 7C–7E; Figures S7C and S7D). This led
us to ask whether the endogenous alkylation damage could be
responsible for synthetic lethality observed in cells with both
ALC1 and HR deficiencies. Indeed, knockdown of MPG sup-
pressed the synthetic lethality between ALC1 and HR defi-
ciencies and rescued PARPi sensitivity in HR-deficient cells.
Hence, we propose that processing of endogenous alkylated
base lesions by MPG creates toxic lesions that underpin both
synthetic lethality between ALC1 and HR and PARPi sensitivity
in HR-deficient cells.
In conclusion, this study shows that ALC1-dependent nucleo-
some remodeling is required for the efficient handover between
DNA glycosylases, PARP1/2, and APEX1 downstream of lesion
excision. While ALC1 loss is compatible with viability and fertility
and is not pro-tumorigenic at an organismal level (Figure 1), loss
of either ALC1 or APEX1 results in sensitivity toMMS, formyl-dU,
and PARPi and synthetic lethality with HRD or ATM loss. Our
data suggest that this is driven by the accumulation of toxic
BER intermediates resulting from lesion excision by a specific
glycosylase. Importantly, we identify processing of alkylated
base damage by MPG as a key driver of synthetic lethality with
HRD in ALC1/ as well as PARPi sensitivity in HRD. Taken
together with PARPi hyper-sensitization and minimal predicted
toxicity of removing or inhibiting ALC1, our work raises the pos-
sibility that selective small-molecule ALC1 inhibitors or de-
graders could provide an important therapeutic option in HRD-
or ATM-deficient cancers, either alone or as a means to enhance
PARPi sensitivity.STAR+METHODS
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RPA-pSer33 Bethyl Cat#A300-246A, RRID:AB_2180847
RPA Abcam Cat#Ab2175, RRID:AB_302873
gH2AX Millipore Cat#05-636, RRID:AB_309864
ATM-pSer1981 Millipore Cat#05-740, RRID:AB_309954
ATM Sigma Aldrich Cat#A1106, RRID:AB_796190
Chk1 Cell Signaling Technology Cat#2360, RRID:AB_2080320
Chk1-pSer345 Cell Signaling Technology Cat#133D3, RRID:AB_331212
Chk2 Millipore Cat#05-649, RRID:AB_2244941
Cleaved Caspase 3 Cell Signaling Technology Cat#9661, RRID:AB_2341188
BRCA1 Millipore Cat#OP107, RRID:AB_213254
BRCA2 Millipore Cat#OP95, AB_206776
ALC1/CHD1L Cell Signaling Technology Cat#13460, RRID:AB_2798225
MBD4 Invitrogen Cat#PA5-51670, RRID:AB_2643787
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RAD51 Millipore Cat#ABE257, RRID:AB_10850319
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SMC1 antibody Abcam Cat# ab21583, RRID:AB_2192477
DAPI Life Technology Cat#D21490
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Swine anti-Rabbit Immunoglobulins/HRP Agilent-Dako Cat#P0399, RRID:AB_2617141
Bacterial and Virus Strains
E. coli Rosetta (DE3) Competent Cells Novagen(Merck) Cat#0954-3CN
One Shot ccdB Survival 2 T1R
Competent Cells
ThermoFisher Cat#A10460





Chemicals, Peptides, and Recombinant Proteins
Doxycycline Sigma-Aldrich Cat#M0503-5X2MG
Blasticidin ThemoFisher Scientific Cat#A1113903
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Hygromycin B ThemoFisher Scientific Cat#10687010
Zeocin ThemoFisher Scientific Cat#R25005
Puromicin ThemoFisher Scientific Cat#A1113803
Lipofectamine 2000 ThemoFisher Scientific Cat#11668019
EDTA-free Complete protease inhibitor
cocktail
Roche Cat#COEDTAF-RO
PhosSTOP phosphatase inhibitor cocktail Roche Cat#PHOSS-RO
4x NuPAGE LDS sample buffer ThemoFisher Scientific Cat#NP0008
ProLong Gold antifade with DAPI Thermo Fisher Scientific Cat#P36931
Lipofectamine RNAiMAX Invitrogen Cat#13778150
QIAquick PCR purification kit QIAGEN Cat#28106
QIAquick Gel Extraction Kit QIAGEN Cat#28706
QIAprep Spin Miniprep Kit QIAGEN Cat# 27106
Veliparib Selleck Chemicals Cat#S1004
Olaparib Selleck Chemicals Cat#S1060
Talazoparib Selleck Chemicals Cat#S7048
Etoposide Sigma Aldrich Cat#BP885
Cisplatin Sigma Aldrich Cat#C2210000
Aphidicolin Sigma Aldrich Cat#A0781-1MG
Hydroxyurea (HU) Sigma Aldrich Cat#H8627-5G
Camptothecin Sigma Aldrich Cat#C9911
Methyl methanesulfonate (MMS) Sigma Aldrich Cat#129925-5G
PARGi Sigma Aldrich Cat#PDD00017273
dU Sigma Aldrich Cat#D5412
5-FU Sigma Aldrich Cat#6627
Formy-dU Gift from Stephen West NA
INDOLE-3-ACETIC ACID (IAA) Sigma-Aldrich Cat#I2886
Resazurin Sigma-Aldrich Cat#R7017
Doxycycline hyclate Sigma-Aldrich Cat#D9891
Subcellular Protein Fractionation Kit Thermo Fisher Cat# 78840
Clarity Western ECL Bio-Rad Cat#1705061
Clarity Max Western ECL Bio-Rad Cat#1705062
Mononucleosomes EpiCypher Cat No. 16-0006
Recombinant human PARG protein Lambrecht et al., 2015 N/A
Recombinant human PARP1 protein Gibbs-Seymour et al., 2016 N/A
Recombinant human ALC1 macro domain
a.a 585-897
This paper N/A
HiLoad 16/600 Superdex 200 pg Sigma-Aldrich GE28-9893-35
Benzonase Nuclease Millipore-Merck E1014







Olaparib Enzo Life Sciences LKT-O4402-M005
Q5 Site-Directed Mutagenesis Kit New England BioLabs Cat#E0554
Diethylnitrosamine Sigma-Aldrich N0756
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Mendeley Data Mendeley https://doi.org/10.17632/xhw58f995c.1
Experimental Models: Cell Lines
Mouse: ALC1 +/+ MEFs #18 This Paper N/A
Mouse: ALC1 +/+ MEFs #19 This Paper N/A
Mouse: ALC1 / MEFs #11 This Paper N/A
Mouse: ALC1 / MEFs #14 This Paper N/A
Human: eHAP iCAS9 #3 ALC1+/+ #1 (Non-
targeting gRNA LentiGuide Hygro)
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/
#11(ALC1 EX2 gRNA LentiGuide Hygro)
This Paper N/A
Human: U2OS Flp-In T-Rex HOST Durocher lab N/A
Human: ALC1 / U2OS Flp-In T-REx This Paper N/A
Human: eHAP iCAS9 #3 ALC1+/+ #1 Non-
targeting gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11
Non-targeting gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1+/+ #1
PARP1 gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11
PARP1 gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1+/+ #1
PARP2 gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11
PARP2 gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1+/+ #1 53BP1
gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11
53BP1 gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1+/+ #1 pLenti
CMV Puro (control)
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11
pLenti CMV Puro (control)
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11
pLenti CMV ALC1 CRISPR-resistant Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11
pLenti CMV ALC1 G750E CRISPR-
resistant Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11
pLenti CMV ALC1 K77R CRISPR-
resistant Puro
This Paper N/A
Human: eHAP iCAS9 #3 Non-targeting
gRNA LentiGuide Hygro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1 EX2 gRNA
LentiGuide Hygro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1+/+ #1 POLQ
gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11
POLQ gRNA LentiGuide Puro
This Paper N/A
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Human: eHAP iCAS9 #3 ALC1+/+ #1 POLB
gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11
POLB gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1+/+ #1 FEN1
gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11
FEN1 gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1+/+ #1 EXO1
gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11
EXO1 gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1+/+ #1 LIG4
gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11 LIG4
gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1+/+ #1 LIG1
gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11 LIG1
gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1+/+ #1 LIG3
gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11 LIG3
gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1+/+ #1 HPF1
gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11
HPF1 gRNA LentiGuide Puro
This Paper N/A
Human: DLD-1 ALC1 NT LentiCRISPR Puro This Paper N/A
Human: DLD-1 BRCA2/ NT
LentiCRISPR Puro
This Paper N/A
Human: DLD-1 ALC1 EX2
LentiCRISPR Puro
This Paper N/A
Human: DLD-1 BRCA2/ ALC1 EX2 NT
LentiCRISPR Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1+/+
#1 UBC13 gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/
#11 UBC13 gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1+/+ #1 ATM
gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11 ATM
gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1+/+ #1 DUT
gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11 DUT
gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1+/+ #1
SMUG1 gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11
SMUG1 gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1+/+ #1 UNG
gRNA LentiGuide Puro
This Paper N/A
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Human: eHAP iCAS9 #3 ALC1/
#11 UNG gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1+/+ #1 MBD4
gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11
MBD4 gRNA LentiGuide Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11
pLenti CMV Puro (control) #2
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11
pLenti CMV ALC1 Puro
This Paper N/A
Human: eHAP iCAS9 #3 ALC1+/+ #1
SMUG1 /
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11
SMUG1 /
This Paper N/A
Human: eHAP iCAS9 #3 ALC1+/+ #1
APEX1 /
This Paper N/A
Human: eHAP iCAS9 #3 ALC1/ #11
APEX1 /
This Paper N/A
Human: HCT116 BARD1AID/AID Nakamura et al., 2019 https://doi.org/10.1038/s41556-019-
0282-9
Human: HCT116 53BP1/ BARD1AID/AID Becker et al., 2020 (bioRxiv) https://doi.org/10.1101/2020.06.01.
127951
Experimental Models: Organisms/Strains
















BRCA1 siGENOME smart-pool Dharmacon M-003461-02
BRCA2 siGENOME smart-pool Dharmacon M-003462-01
MPG ON-TARGETplus Dharmacon L-005146-00-0005





CRISPR Guides This Paper Table S1
Sequencing Barcodes This Paper Table S2
Recombinant DNA
pLenti CMV Puro DEST (w118-1) Addgene #17452
ALC1 CRISPR-R CMV Puro DEST This Paper NA
ALC1 G750E CRISPR-R CMV Puro DEST This Paper NA
ALC1 K77R CRISPR-R CMV Puro DEST This Paper NA
ALC1wt CMV Puro DEST This Paper NA
BFP/GFP Cas9 reporter Addgene #67980
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Edit-R inducible lentiviral Cas9 Horizon Discovery #CAS11229
CRISPR Guides This Paper Table S1
pNIC-CTHF-ALC1 585-897 This paper N/A
pNIC-CTHF-ALC1 585-897(D723A) This paper N/A
Software and Algorithms
Fiji NIH https://imagej.net/Fiji/Downloads
Image Lab 5.2.1 Bio-Rad Laboratories http://www.bio-rad.com/en-uk/product/
image-lab- software?ID = KRE6P5E8Z
Adobe Illustrator 23.11 Adobe https://www.adobe.com/uk/products/
illustrator.html
Adobe Photoshop 20.0.08 Adobe https://www.adobe.com/uk/products/
photoshop.html
Prism 8 GraphPad Software https://www.graphpad.com/
BWA Li and Durbin, 2009 0.5.9-r16
MAGeck Li et al., 2014 0.5.7





High fat diet Teklad TD.06414






Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Simon
Boulton: simon.boulton@crick.ac.uk
Materials availability
Materials associated with the paper are available upon request to Lead Contact, Simon Boulton: simon.boulton@crick.ac.uk
Data and code availability
The code generated during this study are available at GitHub: https://github.com/saphir746/ALC1-HR-survival. Original data for fig-
ures in the paper are available at https://doi.org/10.17632/xhw58f995c.1.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
Mice deficient for ALC1 were generated using an ES cell line Chd1lGt(E305F08)Wrst available from the German Gene Trap Consortium
(GGTC) in which a gene-trap vector rsFROSAbgeo0s containing a b-Geo cassette was inserted between exon 1 and 2. The precise
localization of the gene-trap vector was determined by GGTC and is located at position 4827 in intron 1. Chd1lGt(E305F08)Wrst ES cells
were injected into C57BL/6Jax host blastocysts and implanted into pseudopregnant females. Chimericmicewere obtained and bred
to SV129mice. The resulting heterozygous (Alc1+/) mice were bred to obtain homozygous Alc1/. Genotyping of the offspring wasMolecular Cell 81, 767–783.e1–e11, February 18, 2021 e6
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GAAA; ALC1KO-5, ATTCTGGCAATGGAAGCACT). For longevity studies, mice were allowed to age and observed for development
of disease. The endpoint of the study was set at 23 months but if they appeared unhealthy or got palpable tumors beforehand, an-
imals were sacrificed. They were then subjected to full necropsy.
For epithelial liver tumor development, 2-week-old mice received a single intraperitoneal (i.p.) injection of diethylnitrosamine
(DEN; Sigma-Aldrich) dissolved in saline at a dose of 25 mg/kg body weight. After weaning, mice have been fed with
increasing proportion of high fat diet (Teklad, TD.06414) mixed with normal chow over a 4-week period. All mice were closely moni-
tored and allowed to reach 36 weeks old at the time where livers were harvested and fixed in 10% NBF for further histological
analysis.
All animal experimentations were undertaken in compliance with UK Home Office legislation under the Animals (Scientific Proced-
ures) Act 1986 under project license number 70/8527 and following the ARRIVE guidelines.
For longevity studies, groups of 30 mice of each genotype (Alc1+/+ versus Alc1/) were allowed to age and observed for
development of disease. The endpoint of the study was set at 23 months but if they appeared unhealthy or got palpable tumors be-
forehand, animals were sacrificed. They were then subjected to full necropsy. The sample size was defined using statistical power
analysis (power of 80%–90% with a significance level of 5% (p = 0.05)). Mice culled due to nonspecific phenotypes (e.g., dermatitis,
overgrown teeth and fits) were excluded from this study. Most mice were housed as group of 2-3 per cages. Females were pooled to
avoid single mouse housing and a small proportion of males was single housed.
Randomization was undertaken to remove any biases. Each mouse had a specific ID number that does not indicate the mouse
genotype and were handled blindly by qualified animal technicians throughout the longevity study. Necropsy was done by certified
histopathologists who blindly looked at H&E sections of a selection of organs and wrote a histology report for each mouse.
For the DEN exposure, sample sizes were determined by power calculations.Wewere not pursuing lower penetrance phenotypes,
thus statistically significant data could typically be obtained with around 6 mice per group (age matched mice of a single genotype),
plotted with 95% CI and statistical significance of phenotype-specific differences determined by unpaired Student’s t test. 6
breeding pairs were set up to produce the necessary mice (males only that are Alc1+/+ versus Alc1/). 14 days after their birth,
all male pups were injected with DEN and then genotyped at the time of weaning (3 weeks of age). Females were sacrificed. Only
males with the relevant genotype (Alc1+/+ versus Alc1/) were kept. 2 weeks after weaning, all mice were fed with a gradual
increasing amount of High Fat Diet mixed with normal chow (25%, 50%, 75%, 100%; each step lasted for 1 week). All mice were
fed with 100% high fat diet until they reached the age of 36 weeks. Mice were checked by abdominal palpation at least once a
week for the first 5 months and then twice a week. At the end of the experiment, liver of each mouse was harvested and fixed for
24 h in NBF10%. Nodules were counted by eye and each visible nodule measured with a calliper. Histology of each liver was
then performed blindly by a qualified histopathologist who counted the number of tumors and identified their type following the IN-
HAND nomenclature of the hepatobiliary system (Thoolen et al.,. 2010).
Cell lines
Mouse embryonic fibroblasts (MEFs) have been derived at 13.5dpc using standard protocol and cultured in Dulbecco’s modified
Eagle’s medium (DMEM) (Invitrogen) supplemented with 15% fetal bovine serum and 1% penicillin-streptomycin (Invitrogen).
MEFs immortalized by Large T-SV40 were maintained with 15% FBS. The human haploid chronic myeloid leukemia cell line,
eHAP (Essletzbichler et al., 2014), was purchased fromHorizon Discovery (#C669) andmaintained in IMDMmedium (GIBCO/Thermo
Fisher) supplemented with 10% FBS and Pen/Strep. U2OS Flp-In T-REx were a kind gift from Durocher lab andmaintained in DMEM
medium (GIBCO/Thermo Fisher) supplemented with 10% FBS and Pen/Strep. Wild-type and BRCA2KODLD-1 cells were purchased
from Horizon and maintained in DMEM medium (GIBCO/Thermo Fisher) supplemented with 10% FBS and Pen/Strep. All cell lines
were grown at 37 C and 5% CO2.
METHOD DETAILS
Histology, immunohistochemistry
For histology and post-mortem tissues, samples were fixed in 10%Neutral buffered formalin (NBF), paraffin embedded, sectioned at
4 mm and stained with hematoxylin and eosin. For immunohistochemistry, samples were prepared using standard methods. In brief,
tissue sections were processed for staining by microwaving in 0.01M citrate buffer, pH 6. After incubation with primary antibodies
(Cleaved caspase 3, Cell Signaling, #9664; gH2AX, Millipore #AB5535), samples were incubated with biotinylated secondary anti-
body (Vector) followed by incubation with Avidin Biotin Complex (Vector); slides were developed in 3,30-diaminobenzidine (DAB) sub-
strate (Vector) and counterstained in hematoxylin. Tumors and lymphomas images were taken using a Nikon Digital Sight DS-Ri1
camera paired to a Nikon 90i Eclipse microscope. Imaging software was NIS-Elements AR Ver 4.0, 64bit.
Lentiviral and transduction
To produce lentivirus, 43 106 293FT cells in a 10-cmdishwere transfectedwith packaging plasmids (2.83 mg pLP1, 1.33 mg pLP2 and
1.84 mg pLP/VSVG) along with 5 mg of expression plasmid using 20 mL Lipofectamine 2000 (Life Technologies/Thermo Fisher) as per
the manufacturer’s instructions. Medium was refreshed 12–16 h later. Virus-containing supernatant was collected 36–40 h poste7 Molecular Cell 81, 767–783.e1–e11, February 18, 2021
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The following antibiotics were used for selection of transductants: puromycin (eHAP 0.4 mg ml1; DLD-1 2 mg ml1 each for 48–72 h),
hygromycin (eHAP 400 mg ml1 for 6-10 days) and blasticidin (8 mg ml1, 4–5 days for all cell lines).
Plasmids
G750Emutation was introduced by Q5 site directed mutagenesis (NEB) in human ALC1 pDon221 (Ahel et al., 2009) using primers: F-
GGGCAGAGGTGAGTTATTTACAGCTC, R-CAGTGGCCAGAGTCATCT. CRISPR resistant silent mutations were introduced into
ALC1, ALC1 K77R and ALC1 G750E pDon221 by Q5 site directed mutagenesis (NEB) using primers: F-ATTAGAAGGCGGAG
TAAACTGGCTCGCC, R-TGATAGCTCCTTAGGTGAATCCCTGTCAGC. Expression vectors were made in pLenti CMV Puro DEST
(w118-1) (Addgene#17452) using the Gateway system (Life Technologies/Thermo Fisher) according to the manufacturer’s protocol.
Expression constructs were introduced into ALC1 / eHAP cells by lentiviral transduction.
RNA interference
BRCA1 was targeted with 50 nM siGENOME smart-pool (M-003461-02). BRCA2 was targeted with 50 nM siGENOME smart-pool
(M-003462-01). MPG was targeted with 50 nM ON-TARGETplus (L-005146-00-0005). 50 nM Non-targeting ON-TARGETplus (D-
001810-10) pool was used as a control. For double siRNA transfections 25 nM of each target or control siRNA was used. siRNA ol-
igonucleotides were transfected in Opti-MEM reduced-serummedium using RNAiMAX (Life Technologies/Thermo Fisher). Following
siRNA transfection, cells were seeded either for survival assays (24 h post transfection) or for immunofluorescence, cell cycle, meta-
phase, replication fiber and immunoblot analysis (48 h post transfection).
DNA damaging drugs
PARP inhibitors olaparib, talazoparib and veliparibwere purchased fromSelleck Chemicals.Methyl methanesulfonate (MMS), 5-Flur-
ouracil, HU, CPT, etoposide, cisplatin and aphidicolin were obtained fromSigma. Concentrations and durations of treatment are indi-
cated in the sections below and in the respective figures.
Generation of Dox-inducible Cas9-expressing cells
eHAP iCAS9 cells were transduced with the Edit-R inducible lentiviral Cas9 vector (Horizon Discovery) and transductants were
selected with blasticidin. Single cell clones were then seeded by limiting dilution in a 96 well plate. Cas9 editing efficiency and
Dox regulation was tested as follows. Cells were transduced at a low (0.3) multiplicity of infection (MOI) with BFP/GFPCas9 reporter
(Addgene #67980). Cells were split into ± 1mg/mL Dox 24 h following transduction. Dox containing media was replenished 48 h
following transduction. Cells were analyzed on LRSII BD Bioscience. BFP positive sells were gated to select cells which had been
transduced. The percentage of GFP positive cells was then calculated. Clones were selected that had a low % (< 5%) GFP positive
in the +Dox condition to select for high Cas9 editing activity and high % (> 95%) GFP positive in the -Dox condition to select clones
with tight regulation (Figure S2K).
Generation of CRISPR knockout cell lines
sgRNAs targeting the following sequences are listed in (Table. 1). Guides were cloned into px459v2 (Addgene #62988), px458 (Ad-
degene #48138), LentiCRISPRv2 (Addgene #52961), Lenti-sgRNA-Hygro (Addgene #104991) or Lenti-sgRNA-Puro (Addgene
#104990) as indicated (Table. 1). ALC1+/+ and ALC1/ eHAP were generated by transducing eHAP iCAS9 generated as described
above with NT gRNA or ALC1 gRNA cloned into Lenti-sgRNA-Hygro (Table. 1). Cells were selected in Hygromycin at a concentration
of 400 mgml1 . The resulting NT gRNA and ALC1 gRNA iCAS9 cell lines were then banked. Tomake individual knockout clones, cells
were treated with 1 mg/mL Dox for 72 h and then seeded as single cell clones by limiting dilution. The resulting plates were duplicated
and screened using IF for ALC1. Knockout clones were then confirmed by immunoblotting against ALC1. ALC1/ U2OS Flp-In T-
REx cell lines were generated by the transient transfection of cells with px459 containing guides against ALC1. Clones were isolated
and screened as above. Inducible CRISPR knockout cell lines were generated by transducing ALC1+/+ and ALC1/ iCAS9 cells with
lentivirus produced from the sgRNA constructs listed in (Table. 1) followed by antibiotic selection. Knockout of target proteins was
confirmed by immunoblotting following 72 h 1 mg/mL Dox. SMUG1 and APEX1 KO cell lines were created by transiently transfecting
ALC1+/+ and ALC1/ iCAS9 cells with APEX1 LentiGuide puro and SMUG1 LentiGuide puro. Cells were pulsed with 0.4ug/mL puro
for 2 days and Cas9 expression was induced by treating with 1mg/mL Dox for 72 h. Clones were isolated and screened as above.
Whole-cell extracts, SDS-PAGE and immunoblotting
For whole cell lysates, PBS washed cells were lysed in RIPA Buffer (10 mM Tris-Cl pH 8.0, 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-
100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl, 1x phosphatase (Phos-Stop, Roche) and protease (Complete, EDTA-
free, Roche) inhibitor mixes) on ice for 20 min. Lysates were sonicated with a probe at medium intensity for 5 s in a Soniprep 150
instrument and clarified by centrifugation at 13000 g for 15 min at 4C. Protein concentration was quantified using the DC Protein
Assay (Bio-Rad) according to themanufacturer’s instructions. Proteins were denatured in 2XNuPAGE LDS sample buffer (Invitrogen)
and 1% 2-metcaptoethanol (Sigma-Aldrich) for 5 min at 95C. Proteins were separated by SDS-PAGE using NuPAGE mini gels (In-
vitrogen) and transferred onto 0.2 mm pore Nitrocellulose membrane (Amersham Protran; Sigma-Aldrich). Membranes were blockedMolecular Cell 81, 767–783.e1–e11, February 18, 2021 e8
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overnight at 4C.Membranes were thenwashed 3 times for 10min with TBST, incubated with appropriate secondary antibodies con-
jugated to a horseradish peroxidase (HRP) for 1 h at room temperature and washed again 3 times for 10min with TBST. Immunoblots
were developed using Clarity or Clarity Max Western ECL Substrate (Bio-Rad).
PARP Trapping
Subcellular fractionation was performed using the Subcellular Protein Fractionation Kit for Cultured Cells (Cat# 78840, Thermo
Fisher) according to the manufacturer’s instructions. Chromatin fractions corresponding to 1 3 106 cells were compared to whole
cell lysates corresponding to 150 000 cells, and separated by SDS-PAGE as indicated.
Chromatin Fractionation
4x106 eHAP cells were seeded per 10cmdish 24 h prior to collection. Cells were treated with 10uM formyl-dU or DMSO control for 1 h
prior to collection. Cells were scraped in 1ml ice-cold PBS. 50% of the sample was kept on ice for whole cell control. The remaining
cells were spun down for 4 min at 500 g and resuspended in 200ul CSK buffer (10mM PIPES pH7.0, 100mM NaCl, 300mM Sucrose,
1.5mM MgCL2, 5mM EDTA, 0.5% Triton 1x phosphatase (Phos-Stop, Roche) and protease (Complete, EDTA-free, Roche) inhibitor
mixes)) and incubated on ice for 10 min. Cells were spun down at full speed for 10 s 150ul of supernatant (soluble fraction) was
collected. Residual soluble fraction was removed and the chromatin pellet was washed in 500ul of CSK.Whole cell chromatin pellets
were resuspended in 200ul 1X NuPAGE LDS sample buffer (Invitrogen) and 1% 2-metcaptoethanol (Sigma-Aldrich). 50uL of 4x
NuPAGE LDS sample buffer (Invitrogen) and 4% 2-metcaptoethanol (Sigma-Aldrich) was added to soluble fraction. Samples
were sonicated with a probe at medium intensity for 10 s in a Soniprep 150 instrument and then incubated at 95C for 10 min.
20ul of each fraction was loaded and subjected to SDS-PAGE as above.
CRISPR–Cas9 screening
CRISPR screens were performed as described(Doench et al., 2016). eHAP iCAS9 expressing NT or ALC1 gRNA were transduced
with the lentiviral Brunello library (Addgene #73179-LV) at a lowMOI (0.2–0.3) in 2 biologically independent transductions. Puromy-
cin-containing medium was added the next day to select for transductants. Selection was continued until 72 h post transduction. At
this point the cells from transduction #2 were split into two technical 2 replicates giving 3 replicates in total. Cells were then subcul-
tured in 1 mg/mLDox to induce CAS9 expression for 144 h. Following this, pellets of 40million cells were collected from each replicate
for sequencing of T1. Each of the three replicates was divided into two populations. One was left untreated and to the other 250 nM
Olaparib was added. Cells were grown with or without Olaparib for a further 144 h and subcultured every two days. Sample cell pel-
lets were frozen at each time point for genomic DNA (gDNA) isolation. A library coverage of 3400 cells per sgRNA was maintained at
every step.
gDNA from cell pellets was isolated using the QIAamp Blood Maxi Kit (QIAGEN) and genome-integrated sgRNA sequences were
amplified by ExTaq polymerase (Takara) using P5 and P7 multiplexing barcoded primers (Table. 2). The concentration and quality of
the libraries following gel purification wasmeasured using Qubit and TapeStation, pooled them at 4 nM and sequenced on the HiSeq
4000 with 75 bp reads. Data presented in Table.3.
CRISPR sequencing analysis
Raw data was trimmed by obtaining 20 bp after the first occurrence of ‘‘CACCG’’ in the read sequence. Trimmed reads were then
mapped with BWA (version 0.5.9-r16)(Li and Durbin, 2009) to a database of guide sequences for the human CRISPR Brunello lenti-
viral pooled library downloaded from Addgene (https://www.addgene.org/pooled-library/broadgpp-human-knockout-brunello/)
with the parameters ‘‘-l 20 -k 2 -n 2.’’ sgRNA counts were obtained after filtering the mapped reads for those that had zero mis-
matches, and mapped to the forward strand of the guide sequence. The MAGeck ‘test’ command (version 0.5.7)(Li et al., 2014)
was used to perform the sgRNA ranking analysis between the relevant conditions with parameters ‘‘–norm-method total–remove-
zero both.’’
CellTiter-Glo survival assays
For eHAP and U2OS cell lines, 200 and 150 cells respectively per well were seeded in a 96 well plates, drug treatments were added
18 h following plating and cells were grown for a further 5 days. CellTiter-Glo assay (Promega) was performed as per manufacturer’s
instruction. Luminescence was measured using Beckman Coulter Paradigm detection platform. For drug sensitivity, treated cells
were normalized to untreated samples.
Clonogenic survival assays
For eHAP clonogenic survival assays 200 cells were seeded per well of a 24-well plate in technical triplicate. Drug treatments were
added 18 h following plating and cells were grown for a further 5 days. Surviving colonies were stained using crystal violet and imaged
and quantified using GelCount (Oxford Optronix). For drug sensitivity, treated cells were normalized to untreated samples. For DLD-1
BRCA2+/+ ALC1+/+ and DLD1BRCA2+/+ ALC1/ clonogenic survival assays, 90 cells were seeded per well of a 24-well plate in tech-
nical triplicate. Drug treatments were added 18 h following plating and cells were grown for a further 8 days. For DLD-1 BRCA2/e9 Molecular Cell 81, 767–783.e1–e11, February 18, 2021
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and cells were grown for a further 11 days. For DLD-1 BRCA2/ ALC1-low expressing, 1200 cells were seeded per well of a 24-well
plate in technical triplicate. Drug treatments were added 18 h following plating and cells were grown for a further 11 days. For drug
sensitivity, treated cells were normalized to untreated samples.
Cell cycle analysis by FACS
For EdU/PI Flow Cytometry, cells were labeled for 30 min with 10 mM EdU, fixed in 4% PFA, permeabilized in PBS-Triton 0.3% and
washed in 1% BSA before samples were processed using the Click-iT EdU Flow Cytometry Cell Proliferation Assay (Thermo Fisher)
with Alexa Fluor 488. DNAwas counterstained with Propidium Iodide (10 mg/mL). Newly synthesized DNA (EdU) and DNA content (PI)
were detected using an LSRII (Becton Dickinson). Gating of single cells and cell cycle analysis was performedmanually using FlowJo
(TreeStar).
Protein expression and purification
ALC1 macro domain proteins were expressed in E. coli Rosetta (DE3) cells in Lysogeny Broth supplemented with 50 mg/mL kana-
mycin and 34 mg/mL chloroamphenicol. Cells were induced at OD600 0.6 with 0.35 mM IPTG and grown overnight at 18
C. Cell pel-
lets were resuspended in lysis buffer (50 mM HEPES-NaOH, pH 7.5, 500 mM NaCl, 5% glycerol, 4 mM 2-mercaptoethanol, 10mM
imidazole, protease inhibitor cocktail (Roche), 25 units/mL of benzonase (Sigma-Aldrich), and 2 mg/mL lysozyme and lysed thor-
oughly by Emulsi Flex-C5 homogenizer (Avestin) at 15,000Psi. Lysate was centrifuged for 60 min at 35,000 g and applied to Ni-
NTA agarose resin (50% slurry, QIAGEN) equilibrated to lysis buffer. The proteins were eluted by 500mM imidazole and then puriðed
over a Superdex S-200 (16/600) column in 40 mM HEPES-NaOH, pH 7.5, 200 mM NaCl and 1 mM DTT.
PARP1, PARG and HPF1 were purified as described previously(Lambrecht et al., 2015; Langelier et al., 2011; Suskiewicz
et al., 2020).
Chromosome spreading
To facilitate the analysis of structural chromosome aberrations, cells were incubated for 5 h inmedium containing 330 nMnocodazole
(Sigma). Mitotic cells were swelled in a hypotonic solution (DMEM: deionized water at 1:3 ratio) for 6 min at RT. Subsequently, cells
were fixed with Carnoy’s buffer (freshly made) for 15 min at RT and spun down, this fixation step was repeated four times. The sus-
pension of cells in Carnoy’s buffer (100 ml) was dropped on a clean slide and let dry at RT. Slides were incubated with 3% Giemsa in
PBS for 6 min at RT. After drying, slides were mounted with DPX mountant (Sigma). Images were acquired using an Olympus
FV1000D (InvertedMicroscopeIX81) confocal laser scanning microscope equipped with a PlanApoN 3 60/1.40 NA Oil Sc objective
lens controlled by FV10-ASW software.
Immunofluorescence microscopy
eHAP cells were incubated with 1 mM EdU for 30 min before fixation. Cells were treated with pre-extraction buffer (10 mM Pipes, pH
7.0, 100mMNaCl, 300mM sucrose, 1.5 mMMgCl2, 5 mMEDTA, 0.3mMRNase A and 0.5% Triton X-100) for 3min on ice, then fixed
with 4% formaldehyde at room temperature (RT) for 15 min. Fixed cells were stained for EdU incorporation using Click-iT EdU Im-
aging Kit (Life Technology C10340), then processed for immunofluorescence microscopy (IF). Primary antibodies used are listed in
(Table. 3). Alexa fluorophore-conjugated secondary antibodies were used for detection. DNA was stained using DAPI. Images were
acquired using a Nikon Ti2 microscope fitted with a CSU-W1 spinning disk confocal unit (Yokogawa) and a Prime 95B camera (Pho-
tometrics) using Plan Apochromat 100x/1.45 NA Oil objective lens and controlled by Nikon NIS-Elements. For RAD51, images were
acquired using an Olympus FV1000D (InvertedMicroscopeIX81) confocal laser scanning microscope equipped with a PlanApoN 3
60/1.40 NA Oil Sc objective lens controlled by FV10-ASW software.
Quantification of DNA damage markers
Quantification of DNA damage marker foci and signal intensity was performed by Fiji software.
DNA Fiber assay
DNA fiber assay was performed as described in(Bellelli et al., 2018). Briefly, eHAP ALC1+/+ and ALC1/ transfected with control
siRNA or siRNA targeting BRCA1 or BRCA2, were pulse labeled with 20 mM CldU for 20 min and subsequently with 200 mM IdU
for 20min. After tripsinization and counting, cells were resuspended at a concentration of 5x 105 in PBS and 2.5 mL of cell suspension
were spotted on glass slides and lysed with 7.5 mL of a buffer containing 0.5% SDS, 200 mM Tris-HCL, pH 7.4, and 50 mM EDTA.
Slides were then tilted to allow a stream of DNA to move slowly toward the botton of the slide, briefly air-dried and then fixed in
methanol/acetic acid (3:1) (15 min at R.T). Slides were subsequently denatured in HCl 2,5 M (30 min R.T.), extensively washed in
dH2O and PBS, blocked in 1% BSA/PBS (30 min R.T.) and incubated with rat anti-BrdU monoclonal antibody (1:1000 overnight;
AbD Serotec) and subsequently with mouse anti-BrdU monoclonal antibody (1:500 1 h R.T.; Becton Dickinson). After incubation
with a mixture of Alexa Fluor 488 rabbit anti-mouse and Alexa Fluor 594 goat anti-rat antibodies (1:500 45 min R.T.; Invitrogen) slides
were mounted in PBS/Glycerol 1:1 and finally examined using Axio Imager.M2 (ZEISS) with 63x oil immersion objective and the
Volocity 6.3 software.Molecular Cell 81, 767–783.e1–e11, February 18, 2021 e10
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To identify the presence of ssDNA gaps on ongoing replication forks, we adapted a DNA fiber assay(Bellelli et al., 2018) to include S1
nuclease to degrade ssDNA(Quinet et al., 2017). Briefly, cells were incubated with 20 mM CldU for 30 min and subsequently pulse-
labeled with 200 mM IdU for 60 min. Cells were then permeabilized with CSK-triton (0.5%) for 10 min at R.T. and then washed in PBS
and S1 nuclease buffer (30 mM sodium acetate, 10 mM zinc acetate, 5% glycerol, 50 mM NaCl, pH 4.6). Samples were incubated
with S1 buffer containing (or not) 20 U/mL of S1 nuclease (Invitrogen Cat #18001016) for 30 min at 37C. After a wash in PBS/BSA
0.1%, cells were scraped, centrifuged and resuspended at a concentration of 1-2x103 cells/ml. 2 ml of resuspended nuclei were pi-
petted on the top of a microscope slide and lysed with 8ml of lysis buffer (200 mM Tris–HCl, pH 7.5, 50 mM EDTA, 0.5% SDS). After a
few minutes, slides were tilted to allow the lysate to slowly travel toward the bottom of the slide and air-dried. Slides were then fixed
with Methanol-Acetic acid (3:1) for 15 min at R.T., washed with dH2O and denatured with 2.5 M HCl for 45 min at R.T. After several
washes in dH2O and PBS, slides were blocked with PBS/BSA 1% for 30 min at R.T. and incubated with rat-anti BrdU antibody (Ab-
cam, Cat# ab6326) 1/1000 overnight at 4C and subsequently with mouse anti-BrdU (BD Biosciences, Cat# 347580) 1/500 for 1 h at
R.T. After incubation with a mixture of goat anti-rat Alexa Fluor 594 (Invitrogen, Cat# A-11007) and rabbit anti-mouse Alexa Fluor 488
(Invitrogen, Cat# A-11059) slides were washed, mounted in PBS/Glycerol and images acquired using an AxioImager M1microscope
with 63x objective. Data were reported as IdU/CldU tract ratios.
TCGA survival analysis
1 Data Acquisition
Primary and processed data, notably RNA expression levels for genes CHD1L, BRCA1, BRCA2 and ATM for breast cancer patients
were downloaded from The Cancer Genome Atlas (TCGA)[ref here] in May 2020. Samples with any of the following were excluded
from analysis: (1) ‘‘Not available’’ gene expression values, (2) insufficient survival information and (3) missing date / year of birth. As
the TCGA cohort has already received Ethics Committee Approval, this study did not require additional approval. Our primary out-
comes was cancer mortality at the latest follow-up available, as recorded in the TGCA dataset. Our primary exposure was RNA
expression of gene CHD1L, also known as ACL1 (Chromodomain-helicase-DNA-binding protein 1-like, Chrm. 1 bp 147,242,654-
147,295,765 bps) as well as age. Secondary exposure of interest were RNA levels of the genes BRCA1, BRCA2 and ATM. No sex
adjustment was performed, as all patients in our dataset were female. These processes were performed using R software
version 3.5.0
2 Survival Analysis
Survival analyses were performed using: (1) multivariate Cox proportional hazards regres-sion, and (2) Kaplan-Meier survival curves.
These were performed using the ‘‘survival’’ and ‘‘survminer’’ packages in R. For the Cox regression, we used age as the time metric,
and we regressed survival against terciles of RNA expression of ACL1 to account for potential nonlin-ear associations. Survival data
was left and right censored, with left censoring set at age at diagnosis, and right censoring set at age of death or age at last follow-up.
We investigated the interactive effects of ACL1 expression terciles and expression terciles of BRCA1, BRCA2 and ATM on survival,
and tested for the significance of the interactive terms using likelihood ratio test. Results are quoted in Hazard Ratios (HR) per year of
life. All likelihood ratio tests for interaction are performed using a set of two nested models, where the reduced model is an additive
version of the interaction models. For Kaplan-Meier analyses, age was not included, neither as a confounder nor as a timescale.
Instead, we used days between diagnosis and censoring as a time-scale. Survival profiles were compiled for all combinations of
ACL1 gene expression terciles and BRAC1 / BRCA2 / ATM expression terciles. We present a p value for significance of survival dif-
ference between the gene expression profile. Associations between survival and variables of interest were considered significant if
the p values associated with the results passed below the significance threshold p < 0.05.
QUANTIFICATION AND STATISTICAL ANALYSIS
Sample number (n) indicates the number of independent biological samples in each experiment and are indicated in figure legends or
methods. GraphPad Prism andRwere used for all statistical analysis: Kaplan–Meier plots for survival and calculate significance using
Log-rank (Mantel–Cox) test, unpaired t test or ANOVA multiple comparison tests were used unless stated otherwise.e11 Molecular Cell 81, 767–783.e1–e11, February 18, 2021
